Research Article
BibTex RIS Cite

A Comprehensive Study of the CA-72.4 Tumor Marker Utilization and Cancer Detection: Analysis Based on Ministry of Health Data

Year 2023, Volume: 20 Issue: 2, 279 - 285, 31.08.2023
https://doi.org/10.35440/hutfd.1323865

Abstract

Background: This study aims to explore the relevance and utilization of the CA 72.4 tumor marker in cancer diagnosis, with a particular focus on gastrointestinal tumors and ovarian cancer, based on data from the Minis-try of Health.
Materials and Methods: We conducted a retrospective analysis of health records from the Ministry of Health spanning over five years. The data, consisting of various demographics, including gender, age, and clinical service requests, was statistically analyzed. The rates of reference range exceedance for the CA 72.4 tumor marker, diagnosis times, the ratio of cancer diagnosis, and the cost distribution were among the key aspects evaluated.
Results: The analysis revealed a significant increase in the request for CA 72.4 tests over the years. It was also observed that cancer detection rates slightly increased over time, with a higher percentage in patients testing positive for CA 72.4, primarily requested before diagnosis. The highest requests for the test were made by the Medical Oncology clinic. Furthermore, it was observed that gender and age groups played significant roles in the prevalence of cancer diagnoses.
Conclusions: Our study indicates that the use of CA 72.4 as a tumor marker could be valuable, especially in the detection of certain types of cancer. However, the correlation between a positive CA 72.4 test and a definitive cancer diagnosis requires further investigation, as the sensitivity and specificity of this marker are still subjects of debate. Despite certain limitations, this study offers substantial insights into the utility of CA 72.4 in the current healthcare setting.

References

  • 1. Liang Y, Wang W, Fang C, Raj SS, Li QW, Zhou ZW. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric can-cer. Oncotarget 2016;7:49565–73.
  • 2. Molina R, Auge JM, Alicarte J, Filella X, Vinolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and ma-lignant disease. Tumor Biol 2004;25:56–61.
  • 3. Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to CEA in monitoring patients with colo-rectal cancer. Cancer 1993;72(7):2098–106.
  • 4. Yu J, Zhang S, Zhao B. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. Mol Clin On-col 2016;4(3):441–49.
  • 5. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Casaldi V, et al. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carci-noma. Anticancer Res 1993;13(6B):2409–13.
  • 6. Birinci Ş. A Digital Opportunity for Patients to Manage Their Health: Turkey National Personal Health Record System (The e-Nabız). Balkan Med J 2023;40(3):215.
  • 7. gco.iarc.fr [homepage on the Internet]. WHO: GLOBOCAN [updated 19.05.2020]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
  • 8. Hu PJ, Chen MY, Wu MS, Lin YC, Shih PH, Lai CH, Lin HJ. Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: a multicenter retrospective study. Cancers 2019:11(5):733.
  • 9. Li TT, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predic-tive blood biomarkers in gastric cancer and the potential ap-plication of circulating tumor cells World J. Gastroenter-ol 2018;24(21):2236-46.
  • 10. Chen XZ, Zhang WK, Yang K, Liu J, Wang L, Hu JK, et al. Corre-lation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 2012;39(9):9031-39

CA-72.4 Kullanımı ve Kanser Tespitine İlişkin Kapsamlı Bir Çalışma: Sağlık Bakanlığı Verilerine Dayalı Analiz

Year 2023, Volume: 20 Issue: 2, 279 - 285, 31.08.2023
https://doi.org/10.35440/hutfd.1323865

Abstract

Amaç: Bu çalışma, Sağlık Bakanlığı'ndan alınan verilere dayanarak, özellikle gastrointestinal tümörler ve over kanserine odaklanarak CA-72.4 tümör belirtecinin kanser teşhisindeki önemini ve kullanımını araştırmayı amaçlamaktadır.
Materyal ve Metod: Sağlık Bakanlığı'nın beş yıla yayılan sağlık kayıtlarının retrospektif bir analizini yaptık. Cinsiyet, yaş, klinik hizmet talepleri gibi çeşitli demografik bilgilerden oluşan veriler istatistiksel olarak analiz edildi. CA-72.4 tümör belirtecinin referans aralığını aşma oranları, teşhis süreleri, kanser teşhisi oranı ve maliyet dağılımı değerlendirilen temel unsurlar arasındaydı.
Bulgular: Analiz, yıllar içinde CA-72.4 testleri talebinde önemli bir artış olduğunu ortaya koydu. Ayrıca, kanser tespit oranlarının zaman içinde biraz arttığı, CA-72.4 için pozitif test yapan hastalarda daha yüksek bir yüzdeyle, özellikle teşhisten önce talep edildiği gözlemlendi. Test için en yüksek talepler Tıbbi Onkoloji kliniğinden geldi. Ayrıca cinsiyet ve yaş gruplarının kanser tanılarının yaygınlığında önemli rol oynadığı görülmüştür.
Sonuç: Çalışmamız, CA-72.4'ün bir tümör belirteci olarak kullanılmasının, özellikle belirli kanser türlerinin saptanmasında değerli olabileceğini göstermektedir. Bununla birlikte, pozitif bir CA-72.4 testi ile kesin kanser teşhisi arasındaki korelasyon, bu belirtecin duyarlılığı ve özgüllüğü hala tartışma konusu olduğundan, daha fazla araştırma gerektirir. Bazı sınırlamalara rağmen, bu çalışma CA-72.4'ün mevcut sağlık hizmeti ortamındaki kullanımına ilişkin önemli bilgiler sunmaktadır.

References

  • 1. Liang Y, Wang W, Fang C, Raj SS, Li QW, Zhou ZW. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric can-cer. Oncotarget 2016;7:49565–73.
  • 2. Molina R, Auge JM, Alicarte J, Filella X, Vinolas N, Ballesta AM. Pro-gastrin-releasing peptide in patients with benign and ma-lignant disease. Tumor Biol 2004;25:56–61.
  • 3. Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to CEA in monitoring patients with colo-rectal cancer. Cancer 1993;72(7):2098–106.
  • 4. Yu J, Zhang S, Zhao B. Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer. Mol Clin On-col 2016;4(3):441–49.
  • 5. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Casaldi V, et al. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carci-noma. Anticancer Res 1993;13(6B):2409–13.
  • 6. Birinci Ş. A Digital Opportunity for Patients to Manage Their Health: Turkey National Personal Health Record System (The e-Nabız). Balkan Med J 2023;40(3):215.
  • 7. gco.iarc.fr [homepage on the Internet]. WHO: GLOBOCAN [updated 19.05.2020]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
  • 8. Hu PJ, Chen MY, Wu MS, Lin YC, Shih PH, Lai CH, Lin HJ. Clinical evaluation of CA72-4 for screening gastric cancer in a healthy population: a multicenter retrospective study. Cancers 2019:11(5):733.
  • 9. Li TT, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predic-tive blood biomarkers in gastric cancer and the potential ap-plication of circulating tumor cells World J. Gastroenter-ol 2018;24(21):2236-46.
  • 10. Chen XZ, Zhang WK, Yang K, Liu J, Wang L, Hu JK, et al. Corre-lation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 2012;39(9):9031-39
There are 10 citations in total.

Details

Primary Language English
Subjects Health Services and Systems (Other)
Journal Section Research Article
Authors

Şuayıp Birinci 0000-0001-8104-6198

Mustafa Mahir Ülgü 0000-0003-0825-1851

Early Pub Date August 16, 2023
Publication Date August 31, 2023
Submission Date July 6, 2023
Acceptance Date July 23, 2023
Published in Issue Year 2023 Volume: 20 Issue: 2

Cite

Vancouver Birinci Ş, Ülgü MM. A Comprehensive Study of the CA-72.4 Tumor Marker Utilization and Cancer Detection: Analysis Based on Ministry of Health Data. Harran Üniversitesi Tıp Fakültesi Dergisi. 2023;20(2):279-85.

Harran Üniversitesi Tıp Fakültesi Dergisi  / Journal of Harran University Medical Faculty